In 2016, there were an estimated 10.4 million incident cases of tuberculosis (TB) worldwide, causing 1.7 million deaths (1). Although global TB incidence and mortality rates are falling by 2% and 3% per year, respectively, these declines are far behind what is required to achieve the World Health Organization (WHO) End TB Strategy targets, which aim for 90% and 95% reductions in TB incidence and mortality, respectively, between 2015 and 2035 (2). Consequently, major advances in the understanding of TB pathogenesis (including vaccine development) and transmission, together with new tools for the diagnosis and treatment of both active TB disease and latent infection, are needed. Furthermore, the global importance of nontuberculous mycobacterial (NTM) disease is increasingly being recognized as its incidence rises (3, 4) . This review summarizes the advances in both TB and NTM published in the Journal and other journals in 2017.
Immunology of TB
The immunological mechanisms underlying TB pathogenesis, including susceptibility to infection, progression to disease, recurrence, and response to vaccination, remain poorly understood. Four studies in the Journal provide new insight into TB pathogenesis, with consequences for vaccination and TB control.
The initiation of adaptive immune responses is an integral aspect of the host response to TB. Shah and colleagues investigated the mechanism of action of TOLLIP (Toll-interacting protein), an innate immune response regulator known to be associated with TB (5) . Using cellular immunology approaches, they examined monocyte mRNA expression and TBspecific immune functions, together with the association between TOLLIP variation and bacillus Calmette-Guérin (BCG)-induced T-cell responses and latent TB susceptibility. The authors reported a functional TOLLIP promoter region polymorphism associated with decreased mRNA expression and BCG-specific memory T-cell responses, plus increased TB susceptibility with the TOLLIP-deficient genotype. This was despite there being an increased inflammatory response and decreased mycobacterial replication. The authors postulated that TOLLIP may be a vaccine adjuvant or host-directed therapy target worth further investigation that might enhance immunity and minimize adverse cytokine response.
Leu and colleagues investigated the role of SP110b (a nuclear protein) in host innate immunity to Mycobacterium tuberculosis infection (6) . Using cellular approaches and mouse models, they showed that SP110b downregulates tumor necrosis factor (TNF)-a production of IFN-g active cells, preventing apoptosis. Furthermore, Ipr1, which is a homolog of SP110b, impairs TNF-a production, stopping further pulmonary necrosis. They concluded that by modulating nuclear factor-kB activity, this protein has a significant role in the inflammatory response that protects against TB and may also be a target for future hostdirected therapies.
Scriba and colleagues investigated the effects of previous TB on immunity by assessing whether previous disease leads to a less effective immune response to future TB exposure, thereby increasing the risk of recurrence (7) . They hypothesized that prior TB disease leads to differences between latently infected individuals in the repertoire of M. tuberculosis-derived epitopes recognized by T cells. By assessing T-cell responses in adolescents and adults, they identified two sets of M. tuberculosis epitopes with contrasting immune reactivity in latently infected individuals distinguished by previous disease status. This was seen only in type 2-specific T-cell epitopes, which were less likely to be recognized by those with previous TB in the preceding 6 years than in people with no history of TB. The sets of type 2 T-cell epitopes were homologous to human microbiome bacterial sequences. Furthermore, persistence of the type 1 response and loss of the type 2 response after anti-TB treatment were noted. The authors concluded that there may be persistence of antigens that affect type 1 T-cell epitopes after treatment and/or that type 2-specific responses may be induced by cross-reactive microbiome-derived antigens. Assuming that these results are not due to reexposure and reinfection in this high-TB-burden setting, the findings may have implications for vaccine development because the persistence of antigens could influence the subsequent efficacy of BCG and new vaccines (8) .
Immunization of individuals already infected with M. tuberculosis with BCG or killed bacilli may lead to Koch-type reactions (including a necrotic reaction at the site of injection leading to ulceration). Van Zyl-Smit and colleagues assessed whether a candidate vaccine (AERAS-402 adenovirus serotype 35 replication-deficient vaccine), which contains DNA encoding for mycobacterial antigens 85A, 85B, and TB10.4, is a cause of pulmonary or systemic adverse effects in individuals with current or previously treated TB (9) . All 36 participants with active TB and most (35 individuals [97%] ) individuals with previously treated active TB experienced at least one adverse effect, though these effects were not deemed to be clinically significant. The authors concluded that there was a robust immune response based on the proportion of T cells producing specific cytokines, and, in these populations, there was no evidence of Koch's phenomenon-type reactions attributable to the vaccine.
Diagnosis and Treatment of Active TB Disease
In the Journal, Lessells and colleagues reported the results of a cluster randomized controlled trial examining the impact of point-of-care compared with hospital laboratory implementation of Xpert MTB/RIF (Cepheid), a molecular test for TB and rifampicin resistance (10), on TB treatment initiation among individuals who were HIV positive (92.5%) and/or had risk factors for multidrug-resistant (MDR)-TB (45%) (11) . There was no difference between the point-of-care and laboratory arms in the primary outcome of the proportion of individuals with cultureconfirmed pulmonary TB who had initiated appropriate treatment at 30 days, though the median time to treatment initiation was shorter in the point-of-care arm (1 vs. 7 d). The power to detect a difference in their primary outcome was limited by an impressive 93% of individuals with Xpert MTB/RIF-positive/rifampicin-sensitive disease initiating appropriate therapy within 30 days in the laboratory arm. Most of the delays in treatment initiation beyond 30 days in both arms were in individuals with Xpert MTB/RIF-negative disease or Xpert MTB/RIF-positive/rifampicinresistant disease. This highlights a need for the development of new point-of-care diagnostics with improved sensitivity, as well as improved access to second-line drug-resistance testing and treatment services, which may reduce delays in treatment initiation further.
The WHO recently endorsed the new Xpert Ultra assay (Cepheid) as an alternative to Xpert MTB/RIF (12) . Recent evaluations of Xpert Ultra suggest that it offers improved sensitivity compared with Xpert MTB/RIF in smear-negative TB (63% vs. 46%), HIV-associated pulmonary TB (90% vs. 77%), and HIV-associated TB meningitis (95% vs. 45%) (13) (14) (15) . However, the improved sensitivity may be associated with a modest reduction in specificity, particularly in individuals with a recent history of TB and in high-TB-incidence settings, which requires further evaluation (13) . A further cartridge has been developed for the GeneXpert platform (Cepheid), which detects mutations conferring resistance to fluoroquinolones, aminoglycosides, and isoniazid (16) . Evaluation of the assay in China and Korea has demonstrated promising diagnostic accuracy, suggesting that it could have a role as a point-of-care test in settings with a high prevalence of MDR-TB (17) , although further evaluation in other settings is needed.
A national routine whole-genome sequencing (WGS) service for mycobacterial infections was recently launched in the United Kingdom (18) . This has the potential to offer prompt, reproducible drug resistance profiles to clinicians and may ultimately replace the need for phenotypic drug susceptibility testing. However, the impact of WGS is limited by the need for mycobacterial culture before sequencing, though direct WGS from sputum samples has recently been reported (19) . Universal WGS could enable almost real-time reconstruction of phylogenetic relationships between isolates and may facilitate identification of clusters and inference of transmission with resolution greater than currently available. An issue with WGS is the increasing evidence demonstrating the degree of within-host diversity of M. tuberculosis strains. In the Journal, Metcalfe and colleagues demonstrated the potential role of minority mycobacterial subpopulations in contributing to phenotypic drug resistance (20) . The authors used a targeted, highcoverage next-generation sequencing technique (single-molecule overlapping reads) to resolve discordance between phenotypic drug-resistant (DR) isolates without corresponding Sanger sequencingdetected genotypic resistance variants. They found that minor resistant variants could be identified using single-molecule overlapping reads in 80% of these discordant isolates. This supports the view that microevolution leading to within-host diversity of M. tuberculosis may influence drug susceptibility, though the precise role of these subpopulations in the evolution of acquired drug resistance requires further evaluation (21, 22) . (24) 9-month regimen consisting of moxifloxacin, clofazimine, ethambutol, and pyrazinamide given for 9 months, supplemented by kanamycin, isoniazid, and prothionamide in the first 4 months among patients with MDR-TB without evidence of resistance to fluoroquinolones or injectables (25) . The preliminary results demonstrate similar efficacy, though noninferiority to standard therapy was not formally demonstrated. Final published results are pending (23) . However, there is recognition that, in some settings, only a minority of patients with MDR-TB will be eligible for the 9-month regimen, owing to resistance to second-line drugs (estimated as 4.2 to 11.1% in three European studies) (26) (27) (28) . This highlights an ongoing need for new antimicrobial regimens for MDR-TB and also for hostdirected therapies to improve treatment outcomes (29) . In the Journal, Ganmaa and colleagues reported their randomized controlled trial in which they assessed the impact of high-dose vitamin D 3 on response to antimicrobial therapy in adults with drugsensitive pulmonary TB in Mongolia, with the primary outcome of time to sputum culture conversion (30) . The authors found that supplementation did not reduce time to culture conversion overall, though significant effect modification was noted in individuals with genetic variants in the vitamin D signaling pathway. This supports previous evidence (31) (32) (33) , and together, the results suggest that we should now move on from investigating whether vitamin D can improve PULMONARY, SLEEP, AND CRITICAL CARE UPDATE the outcome of treatment for TB disease when given with standard TB therapy.
Diagnosis of Latent TB Infection
In 2017, the diagnosis of latent TB infection and the risk of progressive TB based on IFN-g release assay (IGRA) results continued to be important themes in the Journal. Conversion of a QuantiFERON-TB (QFT; Qiagen) IGRA from a negative to positive test result likely signals M. tuberculosis infection and carries greater than twofold risk of progression to TB in untreated individuals (34) . However, variation in the definitions of IGRA conversions and reversions can affect the utility of the assay in the programmatic management of latent TB infection.
Using a combined cohort approach, Nemes and colleagues conducted an analysis of retrospective data to derive a stringent risk-validated definition of QFT conversion to improve the consistency of serial testing algorithms (35) . They used data from multiple HIV-negative populations tested with IGRA, which included 5,357 healthy adolescents from a high-risk setting, M. tuberculosis-unexposed individuals from a low-burden setting (control subjects), and patients with definite pulmonary TB. Cohorts were followed for at least two years. Interassay variability was assessed, and distributions of IFN-g response levels were analyzed and correlated with the risk of TB. The authors proposed internally validated risk strata of IFN-g values less than 0.2 IU/ml, 0.2-0.34 IU/ml, 0.35-0.7 IU/ml, and greater than 0.7 IU/ml (tuberculin skin test positivity values of 15%, 53%, 66%, and 91%, respectively). Individuals with values less than 0.2 IU/ml are presumed "true negatives," and those with values greater than 0.7 IU/ml are presumed "true positives" with established M. tuberculosis infection. As expected, all M. tuberculosis-unexposed individuals had IFN-g values less than 0.2 IU/ml, and the majority (87%) of patients with active TB had IFN-g values greater than 0.7 IU/ml. The authors suggested a strict QFT conversion definition of IFN-g value less than 0.2 to greater than 0.7 would improve detection of those likely to progress; converters had a 10-fold higher risk of TB than nonconverters (defined as maintaining values ,0.2 IU/ml over 2 yr). Conversions and reversions tend to be around the manufacturer's suggested threshold (0.35 IU/ml). The authors thus proposed the introduction of a zone of uncertainty for QFT (between 0.2 IU/ml and 0.7 IU/ml), as is done when interpreting T-SPOT.TB (Oxford Immunotec, Inc.) results. Interestingly, individuals with at least one conversion in this zone of uncertainty were shown to have a risk of TB statistically similar to that of nonconverters. Weak immune responses as well as issues affecting assay reproducibility may contribute to conversions in this zone. It will be important to determine the implications of conversion values in the uncertainty zone with respect to clinical utility, the timing of retesting, and TB risk in further independent cohorts (36) . Definitions proposed in this paper would need external validation, especially in HIV-positive individuals and in individuals with other immunosuppressive conditions.
Transmission of TB
Exploring heterogeneity in the transmission dynamics of drug-sensitive and DR TB in communities can offer a powerful strategy for strengthening TB control (37) . Shrestha and colleagues demonstrated the utility of this approach using U.S. data (38) .
TB incidence in the United States has remained low but steady at approximately 3.0 per 100,000 population since 2013. The changing demographic makeup or a plateau in the effect of currently implemented interventions may partly explain this. Foreign-born individuals account for twothirds of new TB cases, with a TB incidence of 15.1 per 100,000 (39). Shrestha and colleagues characterized drivers and dynamics of TB in the relatively highburden states of California, Florida, New York, and Texas to examine state-to-state heterogeneity in TB risk and assess whether the declines in TB incidence would continue in the absence of additional interventions or resources. They developed an individual-based model of TB calibrated to state-specific demographics and TB incidence data stratified by age and foreignborn status. They then used this model to infer differences in the natural history of TB and conduct state-specific 10-year projections of TB from 2015. They found that the size and composition of the foreign-born population and TB transmission dynamics contribute to substantial stateto-state heterogeneity. Without additional resources or further state-specific intervention, the model projected a plateauing of the decline in TB incidence by 2025 in all four states, suggesting that these U.S. states would likely not meet the WHO target of achieving preelimination (incidence ,1 in 100,000) and moving toward elimination by 2035.
Genetic variations in mycobacterial strains can provide novel insights into TB transmission but are less frequently studied than host factors. Two studies in the Journal offered advances in this field. NebenzahlGuimaraes and colleagues used a TB registry and strain collection in the Netherlands to identify mycobacterial genetic markers associated with increased transmissibility and to examine whether these lead to altered in vitro immune responses (40) . Controlling for host factors for clustering, the authors identified a priori a set of 100 drug-sensitive M. tuberculosis strains either least or most likely to be transmitted on the basis of their clustering patterns and analyzed them using WGS and evolutionary convergence approaches. In vitro cytokine production and neutrophil responses to a subset of the strains with or without the identified mutations associated with increased transmissibility were also measured. The authors hypothesized that clustered strains have consistent genetic differences compared with unclustered ones, and that the genes or intergenic regions associated with the differences affect the host immune response. The loci espE, PE-PGRS56, Rv0197, Rv2813-R2814c, and Rv2815-R2816c were identified as targets of convergent evolution among transmissible strains. Four of these regions were subsequently confirmed in an independent strain cohort and functionally validated to demonstrate that mutations in the targets affected in vitro monocyte and T-cell cytokine production, neutrophil reactive oxygen species release, and apoptosis. The 100-strain size used in this study, derived from patients with drug-sensitive TB originating from 44 different countries, is small. The findings need to be validated in larger cohorts of longitudinally collected strains from both high-and low-burden settings to further understand their epidemiological and clinical significance in TB transmission.
Molecular diagnostic tools that can rapidly confirm the presence of TB infection and identify the full range of resistance mutations to anti-TB drugs would PULMONARY, SLEEP, AND CRITICAL CARE UPDATE revolutionize case detection and curtail transmission. The study by Farhat and colleagues partially addressed this challenge (41) . Using a large (N = 1,738), geographically diverse, prospectively collected archive of clinical isolates of DR-TB, the authors aimed to identify molecular determinants of resistance to 13 anti-TB drugs using molecular inversion probes, and they presented a validated prediction model for diagnosing resistance to firstand second-line drugs on the basis of detection of mutations within the full length of 28 presumed DR loci. The main finding was that predicted resistance to rifampicin and isoniazid, the only fully characterized drugs, exceeded 90% sensitivity and specificity but was lower for the other drugs or could not reliably be determined. The number of mutations needed to diagnose resistance was large (238 across 18 genetic loci for the 13 drugs). This presents a challenge for future diagnostic tools, which will have to allow for a high dimension of mutation detection. This is possible with WGS, which would also allow identification of previously undetected or unknown DR loci that code resistance to one or more drugs and thus improve the sensitivity of detection of resistance to anti-TB drugs other than rifampicin and isoniazid. This study illustrates the importance of pooling data across laboratories and geographic regions to aid the development of predictive models for DR-TB with greater accuracy in detecting resistance mutations.
NTM
Pulmonary NTM infections are increasingly common and difficult to successfully treat (4, 42) . Recent work using a populationbased cohort of patients with NTM respiratory isolates in Oregon highlighted the appreciable mortality (.35% at 5 yr), which was often due to patients' coexistent illnesses (43) . However, significant immunocompromise (such as advanced HIV infection) or extensive structural lung disease (for example in cystic fibrosis [CF]) now accounts for a minority of NTM cases. In the United States, chronic pulmonary NTM infection and disease are seen increasingly among people with apparently normal (or near-normal) immunity and minimal initial lung damage (4) . Reasons for this, together with new approaches to treating pulmonary NTM, are the subject of two 2017 Journal publications. These areas were identified by an NTM Research Consortium workshop as some of the main priorities for patient-centered research in clinical and translational science (44) .
Familial clustering of pulmonary NTM disease is rare but has been reported in carefully performed studies (45) . Applying whole-exome sequencing technology to nine families with pulmonary NTM and then including a further 57 sporadic cases (where the unaffected family members acted as control subjects for all tested patients), Chen and colleagues identified a 20-cM (20,000 kb) region on chromosomes 6q12-6q16 with a heterogeneity logarithm of the odds score of 3.9 (.3.3 was regarded as indicating linkage) (46) . This fitted best under a recessive disease model with 100% penetrance and a risk allele frequency of 5%. Using gene-level linkage analysis, the authors determined the genes potentially driving the linkage signals. The TTK protein kinase (TTK) gene, which has a role in regulating proper chromosomal alignment and hence controlling DNA damage and repair, was most strongly associated (46) . It remains to be seen whether this proposed mechanism (where aberrant TTK gene function could result in failure of local innate pulmonary immunity and so allow environmental NTM to colonize, infect, and ultimately cause disease) is relevant to many patients with NTM who have unexplained disease or if it is a phenomenon arising in patients selected by being atypical and hence who were studied. Further work will help to define and characterize the extent of this and other gene defects in NTM-infected populations.
The publication of a randomized controlled trial of liposomal amikacin for inhalation (LAI) (47) is an important step in approaches to developing treatment that, unlike many other therapies for NTM, may be both effective and reasonably tolerated (48) . In the study by Olivier and colleagues (47) , 89 adults (of 136 screened) with treatment-refractory pulmonary NTM received either once-daily LAI or liposomal placebo. The primary endpoint was change in sputum mycobacterial growth after 12 weeks using a semiquantitative scale. This efficacy measure represented transitions between grades of growth on either solid media (with a set range of colony-forming units being graded as different categorical values) or a change from positive to negative in liquid culture. Time to positivity in liquid medium (as a surrogate of mycobacterial load) was not used. Before study enrollment, patients had persistently positive sputum culture results, despite in many cases having received at least 12 months of continuous therapy for NTM. Patients were designated as having either predominately Mycobacterium avium complex (twothirds of subjects) or predominately Mycobacterium abscessus infection (onethird). The majority of subjects had cavitatory NTM disease, and approximately one in five participants had underlying CF.
The trial showed no difference in semiquantitative scale scores between the two arms, though improvements were found in the secondary endpoint of the proportion achieving sputum conversion (in particular for patients with predominantly M. avium complex) and also in the tertiary endpoint of change in 6-minute walk distance. Interestingly, health status measures such as the St. George's Respiratory Questionnaire and a CF-adapted and non-CF NTM-specific questionnaire did not change. This may be explained by dysphonia, cough, and infectious exacerbations of respiratory disease being more common within the LAI arm, all of which would reduce reported health status. The latter is a concern, given that amikacin might be expected to prevent some respiratory infections. However, it is unclear which (if any) organisms were isolated from sputum during the acute deteriorations. It is important to note that LAI was no more likely than placebo to result in audiological changes or impaired renal function. The one death within the LAI arm was believed not to be due to NTM disease or drug treatment. The reasonable tolerability of LAI enables us to hope that, when used for longer durations, it will continue to offer a similar reasonable safety profile.
One issue is whether the addition of a single drug to a potentially failing infection management regimen is wise. In post hoc analysis, individuals who did not respond to LAI had either baseline amikacin resistance within their isolates or developed this subsequently while receiving treatment. Nine (10%) of 89 patients had baseline resistance to amikacin, and a further 5 patients (6%) were resistant at Week 12 or 24 of therapy. This information is helpful in determining who is likely to respond to (and therefore most likely to benefit from) LAI. It also has implications for clinicians who may ask if the drug can be of greater benefit if given earlier in therapy.
PULMONARY, SLEEP, AND CRITICAL CARE UPDATE Conclusions
Research published in the Journal and elsewhere in 2017 has improved knowledge of TB pathogenesis and transmission as well as of the management of latent and active TB. Similarly, new work provides further promising insights regarding NTM. These contributions are critical if we are to achieve the global plan to end TB, though there remains much work to do. n
